Who
Sandra Calvin
SVP, Chief Accounting Officer
Company insider
Files Form 4 as: SVP, Chief Accounting Officer, Travere Therapeutics.
In numbers
- Trades disclosed
- 94
- Buys
- 0
- Sells
- 24
- Bought
- $0
- Sold
- $7.7M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 24 Jan 2022
- Last trade
- 15 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $69K2,500 at $27.50 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $28K1,250 at $22.40 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $33K1,625 at $20.46 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,250 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,625 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $266K4,275 at $62.14 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $50K800 at $62.85 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K300 at $63.66 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,250 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,625 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $69K2,500 at $27.50 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $28K1,250 at $22.40 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $33K1,625 at $20.46 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $266K4,275 at $62.14 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $50K800 at $62.85 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K300 at $63.66 | filing |
| 14 Apr 2026filed 16 Apr 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $56K2,500 at $22.40 | filing |
| 14 Apr 2026filed 16 Apr 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $56K6,250 at $8.93 | filing |
News
Travere (NASDAQ: TVTX) CEO sells 243,735 shares after option exercisesTVTX · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Sandra Calvin; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.